These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 17495819)

  • 1. [Randomized FARVATER study. Part 2. Effect of atorvastatin on endothelial function, distensibility and stiffness of vascular wall].
    Susekov AV; Rozhkova TA; Tripoten' MI; Pogorelova OA; Kulev BD; Balakhonova TV; Zubareva MIu; Masenko VP; Rogozova AN; Kukharchuk VV
    Kardiologiia; 2007; 47(2):25-30. PubMed ID: 17495819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Randomized FARVATER Study. Part 1. Effect of 10 and 20 mg/day atorvastatin on levels of lipids, C-reactive protein, and fibrinogen in patients with ischemic heart disease and hyperlipidemia].
    Susekov AV; Zubareva Mi; Tripoten' MI; RozhkovaT A ; Pogorelova OA; Balakhonova TV; Masenko VP; Kukharchuk VV
    Kardiologiia; 2006; 46(9):4-10. PubMed ID: 17047615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of various approaches to therapy with statins in high risk patients from the point of view of vascular endothelium].
    Kulev BD; Ageev FT
    Kardiologiia; 2009; 49(5):4-10. PubMed ID: 19463127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis.
    Kuryata OV; Yegorova YV
    Kardiol Pol; 2006 Jan; 64(1):44-8; discussion 49-50. PubMed ID: 16444629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of high doses of atorvastatin on the endothelial function of the coronary arteries].
    Simaitis A; Laucevicius A
    Medicina (Kaunas); 2003; 39(1):21-9. PubMed ID: 12576762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study).
    Zieve F; Wenger NK; Ben-Yehuda O; Constance C; Bird S; Lee R; Hanson ME; Jones-Burton C; Tershakovec AM
    Am J Cardiol; 2010 Mar; 105(5):656-63. PubMed ID: 20185012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of atorvastatin treatment on the hemorheologic and hemostatic parameters in chronic cerebrovascular patients].
    Szapáry L; Horváth B; Márton Z; Fehér G; Tóth K; Komoly S
    Orv Hetil; 2008 Jun; 149(24):1117-23. PubMed ID: 18539578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal.
    Taneva E; Borucki K; Wiens L; Makarova R; Schmidt-Lucke C; Luley C; Westphal S
    Am J Cardiol; 2006 Apr; 97(7):1002-6. PubMed ID: 16563905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose atorvastatin in peripheral arterial disease (PAD): effect on endothelial function, intima-media-thickness and local progression of PAD. An open randomized controlled pilot trial.
    Spring S; Simon R; van der Loo B; Kovacevic T; Brockes C; Rousson V; Amann-Vesti B; Koppensteiner R
    Thromb Haemost; 2008 Jan; 99(1):182-9. PubMed ID: 18217152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term effect of low-dose atorvastatin on haemorrheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia.
    Szapary L; Horvath B; Marton Z; Alexy T; Kesmarky G; Habon T; Szots M; Koltai K; Juricskay I; Czopf J; Toth K
    CNS Drugs; 2004; 18(3):165-72. PubMed ID: 14871160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive lipid lowering by statin therapy does not improve vasoreactivity in patients with type 2 diabetes.
    van Etten RW; de Koning EJ; Honing ML; Stroes ES; Gaillard CA; Rabelink TJ
    Arterioscler Thromb Vasc Biol; 2002 May; 22(5):799-804. PubMed ID: 12006393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of therapy with atorvastatin on parameters of postprandial lipemia and factors of inflammation in patients with ischemic heart disease].
    Samoĭlenko EIu; Naumov VG; Tvorogova MG; Ezhov MV; Sergienko IV; Kukharchuk VV
    Kardiologiia; 2007; 47(2):4-8. PubMed ID: 17495815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia.
    Jones PH; McKenney JM; Karalis DG; Downey J
    Am Heart J; 2005 Jan; 149(1):e1. PubMed ID: 15660024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein.
    Beckman JA; Liao JK; Hurley S; Garrett LA; Chui D; Mitra D; Creager MA
    Circ Res; 2004 Jul; 95(2):217-23. PubMed ID: 15178637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Not acute but chronic hypertriglyceridemia is associated with impaired endothelium-dependent vasodilation: reversal after lipid-lowering therapy by atorvastatin.
    de Man FH; Weverling-Rijnsburger AW; van der Laarse A; Smelt AH; Jukema JW; Blauw GJ
    Arterioscler Thromb Vasc Biol; 2000 Mar; 20(3):744-50. PubMed ID: 10712400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of 40 mg versus 10 mg of atorvastatin on oxidized low-density lipoprotein, high-sensitivity C-reactive protein, circulating endothelial-derived microparticles, and endothelial progenitor cells in patients with ischemic cardiomyopathy.
    Huang B; Cheng Y; Xie Q; Lin G; Wu Y; Feng Y; Gao J; Xu D
    Clin Cardiol; 2012 Feb; 35(2):125-30. PubMed ID: 22271072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification].
    Li XP; Duan J; Zhao SP; Tan MY; Xu ZM; Zhang DQ
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(34):2399-403. PubMed ID: 17156651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Noninvasive assessment of the effect of atorvastatin on coronary microvasculature and endothelial function in patients with dyslipidemia].
    Tomás JP; Moya JL; Campuzano R; Barrios V; Megías A; Ruiz S; Catalán P; Recarte MA; Muriel A
    Rev Esp Cardiol; 2004 Oct; 57(10):909-15. PubMed ID: 15469787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia.
    Karalis DG; Ishisaka DY; Luo D; Ntanios F; Wun CC
    Am J Cardiol; 2007 Aug; 100(3):445-9. PubMed ID: 17659926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Changes of elastic properties of magistral arteries in patients with ischemic heart disease during treatment with atorvastatin and simvastatin].
    Iliukhin OV; Kalganova EL; Babkin AA; Lopatin IuM
    Kardiologiia; 2005; 45(12):31-4. PubMed ID: 16353044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.